NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo (DRC) has approved the company’s proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The approval marks a significant step forward in the development of a potentially more accessible treatment for Ebola, which has historically required intravenous administration.
According to the company, NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses, and it is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, to its knowledge. This oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments are often difficult to deploy and scale.
The next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. NanoViricides noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. This dual approval pathway could accelerate the availability of the treatment for both diseases.
The company emphasized that NV-387 is its lead drug candidate, with plans to develop it for a range of viral infections including RSV, COVID-19, Long COVID, Influenza, mpox, and measles. The nanoviricide technology underlying NV-387 is based on intellectual property licensed from TheraCour Pharma, Inc.
For more information, visit the company’s newsroom at https://nnw.fm/NNVC.
